PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

HF Treatment from Symptom Relief to Disease Management - New analysis from Frost & Sullivan reveals that the U.S. Heart Failure Emerging Markets earned revenue of $1.33 billion in 2004 and estimates to reach $4.13 billion in 2011.
HF Treatment from Symptom Relief to Disease Management

 

NewswireToday - /newswire/ - San Antonio, TX, United States, 2006/03/24 - New analysis from Frost & Sullivan reveals that the U.S. Heart Failure Emerging Markets earned revenue of $1.33 billion in 2004 and estimates to reach $4.13 billion in 2011..

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

As evidence amounts that it is now a progressive condition, the understanding of heart failure, a condition often treated only for its bothersome symptoms, is being transformed. The move towards treating “high risk” patients who currently have mild or no symptoms expects to expand the market revenue for pharmaceutical market participants.

New analysis from Frost & Sullivan reveals that the U.S. Heart Failure Emerging Markets earned revenue of $1.33 billion in 2004 and estimates to reach $4.13 billion in 2011.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants an overview of the latest analysis of the U.S. Heart Failure Emerging Markets, then send an e-mail to Melina Trevino - Corporate Communications at melina.trevino[.]frost.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via email upon receipt of the above information.

“Followed by landmark trials evaluating the efficacy of a new medication, as part of an already complex drug regimen, the current model of heart failure drug development is not likely to be sustained indefinitely,” notes Frost & Sullivan Research Analyst Linda Liu. “Critical factors that contribute to patient’s treatment with every possible beneficial drug are the lack of comparative clinical trials and the ability to develop a personalized drug regimen for patients.”

With issues still surrounding comparability between different therapeutic classes, such as ACE inhibitors and beta-blockers, and ACE inhibitors and ARBs, there is no significant progress in streamlining the drug regimen. In addition, with multiple novel products in the pipeline, deciphering which products should be part of the standard drug regimen is something that needs addressing, not only in practice but also in large-scale clinical trials.

In the U.S. heart failure market, landmark studies are changing the management of heart failure and expect to play an increasing role in guiding treatment and competition in this market. Physicians are currently changing their treatment practices in response to long-term studies such as VALIANT.

“Competitors are investing heavily in such trials, which take on average four to seven years and this is becoming more and more of an order qualifier in this market,” notes Liu. “This expects to put barriers in place for small companies that do not have the resources to invest in such costly trials.”

Small pharmaceutical companies who are positioned to enter the market are encouraged to enter into marketing and development partnerships with large pharmaceutical companies in order to leverage the financial resources needed to achieve success in the heart failure market.

U.S. Heart Failure Markets, a part of the Pharmaceuticals Subscription (9611), provides an overview and outlook for the market. This research includes detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews are available to the press.

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Medical Services/Equipment articles,
CATCH Visitors via Your Competitors Announcements!


HF Treatment from Symptom Relief to Disease Management

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Melina Trevino 
210.247.2440 melina.trevino[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Medical Services/Equipment via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Medical Services/Equipment Most Recent Related Newswires:

Frost & Sullivan Recognizes Ventec Life Systems for New Product Innovation - Game-changing, Modular Respiratory System, VOCSN
BD Expands Genomics Portfolio with New Single Cell Platform for RNA Expression Analysis
GE Healthcare Advances the Delivery of Cell Therapies with New Thawing Technology
Ansell Limited Announces the Closing of the Sale of its Sexual Wellness Business
PQ Bypass Earns Frost & Sullivan’s European Technology Innovation Award for its Proprietary DETOUR System for Percutaneous Bypass
Curaçao EMS Uses ZOLL Autopulse to Save Tourist in Sudden Cardiac Arrest
ZOLL to Showcase Expanded Portfolio of AEDs at Caravan Salon 2017
MDxHealth Announces Service Agreement with Kaiser Southern California Permanente Medical Group
Frost & Sullivan Lauds CytoSorbents for Leading the Critical Care Immunotherapy Segment with its Novel Blood Purification Solution, CytoSorb®
MVZ Dr. Stein & Kollegen First German Medical Laboratory to Offer the SelectMDx for Prostate Cancer Test
Datalogic Announces New Healthcare Memor X3 HC Mobile Computer
Neuronix Ltd Announces the First Group of Mild to Moderate Alzheimer Patients to be Successfully Treated by The NeuroAD™ Therapy System
SelectMDx to be Distributed Across Middle East by IPS Genomix
GE Healthcare Partners with Oritain to Introduce Independent Test to Confirm Country of Origin of Fetal Bovine Serum
Saebo, Inc. Awarded Patent for Low-Profile Stroke Recovery Glove

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  SKS Media | SKS Associates Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)